FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”
In Brief: Shingleton Chairs Cancer Control Committee; Joftes, Price Head Review, Organ Site Branches
NDA For MeCCNU Turned Down By Oncologic Drugs Advisory Committee
Schepartz New DCT Deputy Director; DeVita To Continue As Clinical Director
Nine Cancer Act Changes Considered By NCAB Subcommittee
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”